Posaconazole: An oral triazole with an extended spectrum of activity

Annals of Pharmacotherapy

Volumn 42, Issue 10, 2008, Pages 1429-1438

  Rachwalski, Erik J ^a   Wieczorkiewicz, Jeffrey T ^a   Scheetz, Marc H ^a,b,c  

^a NORTHWESTERN MEMORIAL HOSPITAL   (United States)

^b Chicago College of Pharmacy   (United States)

^c MIDWESTERN UNIVERSITY   (United States)

Author keywords

Antifungal; Azole; Noxafil; Posaconazole; SCH 56592

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; ASTEMIZOLE; CALCIUM CHANNEL BLOCKING AGENT; CASPOFUNGIN; CIMETIDINE; CISAPRIDE; CYCLOSPORIN; ERGOT ALKALOID; FLUCONAZOLE; HALOFANTRINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ITRACONAZOLE; MICAFUNGIN; PHENYTOIN; PIMOZIDE; POSACONAZOLE; QUINIDINE; RAPAMYCIN; RIFABUTIN; TACROLIMUS; TERFENADINE; VINBLASTINE; VINCRISTINE; VORICONAZOLE;

ANTIFUNGAL ACTIVITY; AREA UNDER THE CURVE; ASPERGILLOSIS; CANCER PATIENT; CHEMOPROPHYLAXIS; CLINICAL TRIAL; COCCIDIOIDOMYCOSIS; CRYPTOCOCCAL MENINGITIS; DIARRHEA; DRUG COST; DRUG MONITORING; DRUG WITHDRAWAL; ESOPHAGUS CANDIDIASIS; FEVER; HEADACHE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOPLASMOSIS; HUMAN; HYPOTENSION; INFECTION PREVENTION; MEDLINE; MINIMUM INHIBITORY CONCENTRATION; MUCORMYCOSIS; MYCOSIS; NAUSEA; NEUROTOXICITY; PRIORITY JOURNAL; QT PROLONGATION; REVIEW; SINGLE DRUG DOSE; THRUSH; VOMITING;

ANIMALS; ANTIBIOTICS, ANTIFUNGAL; CLINICAL TRIALS AS TOPIC; DRUG MONITORING; DRUG RESISTANCE, FUNGAL; HUMANS; MICROBIAL SENSITIVITY TESTS; MYCOSES; RISK FACTORS; TRIAZOLES;

EID: 52949140624     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1L005     Document Type: Review

References (67)

1. Product information. Noxafil (posaconazole). Kenilworth, NJ: Schering Corporation, October 2006.
2. Keating GM. Posaconazole. Drugs 2005;65:1553-67; discussion 68-9.
3. Torres HA, Hachem RY, Chemaly RF, Kontoyiannis DP, Raad II. Posaconazole: a broad-spectrum triazole antifungal. Lancet Infect Dis 2005;5:775-85.
4. Kwon DS, Mylonakis E. Posaconazole: a new broad-spectrum antifungal agent. Expert Opin Pharmacother 2007;8:1167-78.
5. Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard - second edition. NCCLS document M27-A2 [ISBN 1-56238-469-4]. National Committee for Clinical Laboratory Standards, Wayne, PA, 2002.
6. Pfaller MA, Messer SA, Hollis RJ, Jones RN. In vitro activities of posaconazole (Sch 56592) compared with those of itraconazole and fluconazole against 3,685 clinical isolates of Candida spp. and Cryptococcus neoformans. Antimicrob Agents Chemother 2001;45:2862-4.
7. Pfaller MA, Messer SA, Boyken L, et al. Global trends in the antifungal susceptibility of Cryptococcus neoformans (1990 to 2004). J Clin Microbiol 2005;43:2163-7.
8. Diekema DJ, Messer SA, Hollis RJ, Jones RN, Pfaller MA. Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi. J Clin Microbiol 2003;41:3623-6.
9. Espinel-Ingroff A. Comparison of in vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. J Clin Microbiol 1998;36:2950-6.
10. Catanzaro A, Cloud GA, Stevens DA, et al. Safety, tolerance, and efficacy of posaconazole therapy in patients with nonmeningeal disseminated or chronic pulmonary coccidioidomycosis. Clin Infect Dis 2007;45:562-8.
11. Kanafani ZA, Perfect JR. Resistance to antifungal agents: mechanisms and clinical impact. Clin Infect Dis 2008;46:120-8.
12. Mann PA, Parmegiani RM, Wei SQ, et al. Mutations in Aspergillus fumigatus resulting in reduced susceptibility to posaconazole appear to be restricted to a single amino acid in the cytochrome P450 14alpha-demethylase. Antimicrob Agents Chemother 2003;47:577-81.
13. Mellado E, Garcia-Effron G, Alcazar-Fuoli L, Cuenca-Estrella M, Rodriguez-Tudela JL. Substitutions at methionine 220 in the 14alpha-sterol demethylase (Cyp51A) of Aspergillus fumigatus are responsible for resistance in vitro to azole antifungal drugs. Antimicrob Agents Chemother 2004;48:2747-50.
14. Anstead GM, Martinez M, Graybill JR. Control of a Candida glabrata prosthetic endovascular infection with posaconazole. Med Mycol 2006;44:273-7.
15. Tobon AM, Correa AL, Arango M, de Bedout C, Restrepo A. Posaconazole therapy for severe abdominal candidiasis: a case report. Rev Iberoam Micol 2004;21:79-81.
16. Vazquez JA, Skiest DJ, Tissot-Dupont H, Lennox JL, Boparai N, Isaacs R. Safety and efficacy of posaconazole in the long-term treatment of azole-refractory oropharyngeal and esophageal candidiasis in patients with HIV infection. HIV Clin Tri 2007;8:86-97.
17. Skiest DJ, Vazquez JA, Anstead GM, et al. Posaconazole for the treatment of azole-refractory oropharyngeal and esophageal candidiasis in subjects with HIV infection. Clin Infect Dis 2007;44:607-14.
18. Li X, Brown N, Chau AS, et al. Changes in susceptibility to posaconazole in clinical isolates of Candida albicans. J Antimicrob Chemother 2004;53:74-80.
19. Xiao L, Madison V, Chau AS, Loebenberg D, Palermo RE, McNicholas PM. Three-dimensional models of wild-type and mutated forms of cytochrome P450 14alpha-sterol demethylases from Aspergillus fumigatus and Candida albicans provide insights into posaconazole binding. Antimicrob Agents Chemother 2004;48:568-74.
20. Chau AS, Mendrick CA, Sabatelli FJ, Loebenberg D, McNicholas PM. Application of real-time quantitative PCR to molecular analysis of Candida albicans strains exhibiting reduced susceptibility to azoles. Antimicrob Agents Chemother 2004;48:2124-31.
21. Courtney R, Pai S, Laughlin M, Lim J, Batra V. Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults. Antimicrob Agents Chemother 2003;47:2788-95.
22. Gubbins PO, Krishna G, Sansone-Parsons A, et al. Pharmacokinetics and safety of oral posaconazole in neutropenic stem cell transplant recipients. Antimicrob Agents Chemother 2006;50:1993-9.
23. Ezzet F, Wexler D, Courtney R, Krishna G, Lim J, Laughlin M. Oral bioavailability of posaconazole in fasted healthy subjects: comparison between three regimens and basis for clinical dosage recommendations. Clin Pharmacokinet 2005;44:211-20.
24. Ullmann AJ, Comely OA, Burchardt A, et al. Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection. Antimicrob Agents Chemother 2006;50:658-66.
25. Courtney R, Wexler D, Radwanski E, Lim J, Laughlin M. Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults. Br J Clin Pharmacol 2004;57:218-22.
26. Courtney R, Radwanski E, Lim J, Laughlin M. Pharmacokinetics of posaconazole coadministered with antacid in fasting or nonfasting healthy men. Antimicrob Agents Chemother 2004;48:804-8.
27. Courtney R, Sansone A, Smith W, et al. Posaconazole pharmacokinetics, safety, and tolerability in subjects with varying degrees of chronic renal disease. J Clin Pharmacol 2005;45:185-92.
28. Krishna G, Martinho M, Chandrasekar P, Ullmann AJ, Patino H. Pharmacokinetics of oral posaconazole in allogeneic hematopoietic stem cell transplant recipients with graft-versus-host disease. Pharmacotherapy 2007;27:1627-36.
29. Administrative and Correspondence Documents. Schering Corporation. New Drug Application No.: 022003. Center for Drug Evaluation and Research, 2006. www.fda.gov/cder/approval/index.htm (accessed 2007 Oct 25).
30. Sansone-Parsons A, Krishna G, Simon J, et al. Effects of age, gender, and race/ethnicity on the pharmacokinetics of posaconazole in healthy volunteers. Antimicrob Agents Chemother 2007;51:495-502.
31. Clinical Pharmacology and Biopharmaceutics Review(s). Schering Corporation. New Drug Application No.: 022003. Center for Drug Evaluation and Research, 2006. www.fda.gov/cder/approval/index.htm (accessed 2007 Oct 25).
32. Krieter P, Flannery B, Musick T, Gohdes M, Martinho M, Courtney R. Disposition of posaconazole following single-dose oral administration in healthy subjects. Antimicrob Agents Chemother 2004;48:3543-51.
33. Wexler D, Courtney R, Richards W, Banfield C, Lim J, Laughlin M. Effect of posaconazole on cytochrome P450 enzymes: a randomized, open-label, two-way crossover study. Eur J Pharm Sci 2004;21:645-53.
34. Andes D. Pharmacokinetics and pharmacodynamics of antifungals. Infect Dis Clin North Am 2006;20:679-97.
35. Andes D, Marchillo K, Conklin R, et al. Pharmacodynamics of a new triazole, posaconazole, in a murine model of disseminated candidiasis. Antimicrob Agents Chemother 2004;48:137-42.
36. Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007;356:348-59.
37. Ullmann AJ, Lipton JH, Vesole DH, et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 2007;356:335-47.
38. Statistical Review(s). Schering Corporation. New Drug Application No.: 022003. Center for Drug Evaluation and Research, 2006. www.fda.gov/cder/ approval/index.htm (accessed 2007 Oct 25).
39. Vazquez JA, Skiest DJ, Nieto L, et al. A multicenter randomized trial evaluating posaconazole versus fluconazole for the treatment of oropharyngeal candidiasis in subjects with HIV/AIDS. Clin Infect Dis 2006;42:1179-86.
40. Walsh TJ, Raad I, Patterson TF, et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis 2007;44:2-12.
41. Raad II, Hanna HA, Boktour M, et al. Novel antifungal agents as salvage therapy for invasive aspergillosis in patients with hematologic malignancies: posaconazole compared with high-dose lipid formulations of amphotericin B alone or in combination with caspofungin. Leukemia 2008;22:496-503.
42. van Burik JA, Hare RS, Solomon HF, Corrado ML, Kontoyiannis DP. Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. Clin Infect Dis 2006;42:e61-5.
43. Greenberg RN, Mullane K, van Burik JA, et al. Posaconazole as salvage therapy for zygomycosis. Antimicrob Agents Chemother 2006;50:126-33.
44. Mullane K, Toor AA, Kalnicky C, Rodriguez T, Klein J, Stiff P. Posaconazole salvage therapy allows successful allogeneic hematopoietic stem cell transplantation in patients with refractory invasive mold infections. Transplant Infect Dis 2007;9:89-96.
45. Vehreschild JJ, Kruger K, Kurzai O, et al. Salvage therapy of refractory chronic disseminated candidiasis in a patient with acute myeloid leukaemia and secondary prophylaxis during allogeneic stem cell transplantation. Mycoses 2006;49(suppl 1):42-7.
46. Brugiere O, Dauriat G, Mal H, et al. Pulmonary mucormycosis (zygomycosis) in a lung transplant recipient: recovery after posaconazole therapy. Transplantation 2005;80:1361-2.
47. Harada AS, Lau W. Successful treatment and limb salvage of mucor necrotizing fasciitis after kidney transplantation with posaconazole. Hawaii Med J 2007;66:68-71.
48. Lodge BA, Ashley ED, Steele MP, Perfect JR. Aspergillus fumigatus empyema, arthritis, and calcaneal osteomyelitis in a lung transplant patient successfully treated with posaconazole. J Clin Microbiol 2004;42:1376-8.
49. Tobon AM, Arango M, Fernandez D, Restrepo A. Mucormycosis (zygomycosis) in a heart-kidney transplant recipient: recovery after posaconazole therapy. Clin Infect Dis 2003;36:1488-91.
50. Herbrecht R, Kessler R, Kravanja C, Meyer MH, Waller J, Letscher-Bru V. Successful treatment of Fusarium proliferatum pneumonia with posaconazole in a lung transplant recipient. J Heart Lung Transplant 2004;23:1451-4.
51. Pitisuttithum P, Negroni R, Graybill JR, et al. Activity of posaconazole in the treatment of central nervous system fungal infections. J Antimicrob Chemother 2005;56:745-55.
52. Clark B, Foster R, Tunbridge A, Green S. A case of disseminated histoplasmosis successfully treated with the investigational drug posaconazole. J Infect 2005;51:e177-80.
53. Restrepo A, Tobon A, Clark B, et al. Salvage treatment of histoplasmosis with posaconazole. J Infect 2007;54:319-27.
54. Anstead GM, Corcoran G, Lewis J, Berg D, Graybill JR. Refractory coccidioidomycosis treated with posaconazole. Clin Infect Dis 2005;40:1770-6.
55. Stevens DA, Rendon A, Gaona-Flores V, et al. Posaconazole therapy for chronic refractory coccidioidomycosis. Chest 2007;132:952-8.
56. Raad II, Hachem RY, Herbrecht R, et al. Posaconazole as salvage treatment for invasive fusariosis in patients with underlying hematologic malignancy and other conditions. Clin Infect Dis 2006;42:1398-403.
57. Gupta S, Almyroudis NG, Battiwalla M, et al. Successful treatment of disseminated fusariosis with posaconazole during neutropenia and subsequent allogeneic hematopoietic stem cell transplantation. Transpl Infect Dis 2007;9:156-60.
58. Schering-Plough. POS vs FLU for first line treatment of coccidioidomycosis (Study P04558). ClinicalTrials.gov Identifier: NCT00423267. www.clinicaltrials.gov/ct2/show/NCT00423267?term=posaconazole&rank=11 (accessed 2007 Dec 28).
59. Schering-Plough. A study to evaluate efficacy and safety of four posaconazole regimens with placebo and terbinafine in the treatment of toenail onychomycosis (Study P05082). ClinicalTrials.gov Identifier: NCT00491764.www.clinicaltrials.gov/ct2/show/NCT00491764?term= posaconazole&rank=9 (accessed 2007 Dec 28).
60. Kim H, Kumari P, Lin CC, Nomeir AA. Simultaneous high-performance liquid chromatographic determination of SCH 59884 (phosphate ester prodrug of SCH 56592), SCH 207962 and SCH 56592 in dog plasma. J Pharm Biomed Anal 2002;27:295-303.
61. Raad II, Graybill JR, Bustamante AB, et al. Safety of long-term oral posaconazole use in the treatment of refractory invasive fungal infections. Clin Infect Dis 2006;42:1726-34.
62. Sansone-Parsons A, Krishna G, Martinho M, Kantesaria B, Gelone S, Mant TG. Effect of oral posaconazole on the pharmacokinetics of cyclosporin and tacrolimus. Pharmacotherapy 2007;27:825-34.
63. Saad AH, DePestel DD, Carver PL. Factors influencing the magnitude and clinical significance of drug interactions between azole antifungals and select immunosuppressants. Pharmacotherapy 2006;26:1730-44.
64. Krishna G, Parsons A, Kantesaria B, Mant T. Evaluation of the pharmacokinetics of posaconazole and rifabutin following co-administration to healthy men. Curr Med Res Opin 2007;23:545-52.
65. Krishna G, Sansone-Parsons A, Kantesaria B. Drug interaction assessment following concomitant administration of posaconazole and phenytoin in healthy men. Curr Med Res Opin 2007;23:1415-22.
66. Red book. 2007 ed. Montvale, NJ: Thomson Healthcare Inc., 2007.
67. De Pauw BE, Donnelly JP. Prophylaxis and aspergillosis - has the principle been proven? N Engl J Med 2007;356:409-11.